Biotech · Public company · Cambridge, MA, US
Amylyx Pharmaceuticals, Inc.
Ticker AMLX · SEC CIK 0001658551
Track this companyFree. Adds Amylyx Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials123 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline7
- AMX0035Phase 3 · Progressive Supranuclear PalsyClinicalTrials.gov · fetched Nov 12, 2026
- AMX0035Phase 3 · Amyotrophic Lateral SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- AvexitidePhase 3 · Post Bariatric HypoglycemiaClinicalTrials.gov · fetched Nov 12, 2026
- AMX0035Phase 2 · ALSClinicalTrials.gov · fetched Nov 12, 2026
- AMX0035Phase 2 · Wolfram SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- AMX0035Phase 2 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AMX0114Phase 1 · ALSClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials12
- Avexitide for Treatment of Post-Bariatric HypoglycemiaPHASE3 · ACTIVE_NOT_RECRUITING · started Apr 29, 2025ClinicalTrials.gov NCT06747468 · fetched Nov 12, 2026
- AMX0114 in Adult Participants With Amyotrophic Lateral SclerosisPHASE1 · RECRUITING · started Apr 7, 2025ClinicalTrials.gov NCT06665165 · fetched Nov 12, 2026
- AMX0035 and Progressive Supranuclear PalsyPHASE2_PHASE3 · COMPLETED · started Dec 21, 2023ClinicalTrials.gov NCT06122662 · fetched Nov 12, 2026
- AMX0035 in Adult Patients With Wolfram SyndromePHASE2 · ACTIVE_NOT_RECRUITING · started Mar 3, 2023ClinicalTrials.gov NCT05676034 · fetched Nov 12, 2026
- Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis TreatmentPHASE3 · UNKNOWN · started Oct 28, 2021ClinicalTrials.gov NCT05021536 · fetched Nov 12, 2026
- Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALSPHASE1_PHASE2 · UNKNOWN · started Aug 5, 2021ClinicalTrials.gov NCT04987671 · fetched Nov 12, 2026
- A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)PHASE2_PHASE3 · COMPLETED · started Nov 22, 2020ClinicalTrials.gov NCT04516096 · fetched Nov 12, 2026
- Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's DiseasePHASE2 · COMPLETED · started Sep 14, 2018ClinicalTrials.gov NCT03533257 · fetched Nov 12, 2026
- Open Label Extension Study of AMX0035 in Patients With ALSPHASE2 · COMPLETED · started Mar 29, 2018ClinicalTrials.gov NCT03488524 · fetched Nov 12, 2026
- AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)PHASE2 · COMPLETED · started Jun 22, 2017ClinicalTrials.gov NCT03127514 · fetched Nov 12, 2026
- An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric HypoglycemiaAVAILABLEClinicalTrials.gov NCT07582874 · fetched Nov 12, 2026
- An Intermediate Size Expanded Access Protocol of AMX0035 for ALSAPPROVED_FOR_MARKETINGClinicalTrials.gov NCT05286372 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 18, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 18, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 24, 2026 · fetched Nov 12, 2026